Top of this page
Skip navigation, go straight to the content

ucb-usa.com Responsibility Our Response to COVID-19
 

Our Response to the COVID-19 Pandemic

 

Patients are at the heart of everything we do, and UCB is committed to helping those impacted by the novel coronavirus, COVID-19. This includes helping patients maintain access to and answering any questions about UCB medicines, as well as putting patient and community care first in all our actions during these uncertain times.

The evolving COVID-19 pandemic has placed tremendous strain on medical healthcare systems worldwide as they focus on the ongoing extraordinary medical emergency. Taking this into consideration, UCB has taken measures to protect the patients we serve and others around the world. For information on our response, please check out the Frequently Asked Questions below.

 

Clinical Studies Information

In March 2020, the evolving COVID-19 pandemic led UCB to halt recruitment into ongoing clinical studies and delay all new study starts. This decision was taken in the interest of public health safety and to help reduce the strain on healthcare systems across the world during a time of extraordinary medical emergency. As of mid-May 2020, UCB began to restart clinical study recruitment, including new study starts, at clinical trials sites that meet our restart criteria.

UCB continues to proactively monitor the COVID-19 situation and will take any necessary precautionary steps in the interest of public health. Healthcare professionals and patients with questions related to UCB medicines can contact UCBCares / UCB Medical Information teams across the globe. Contact details can be found here.

Contact ucbCARES

image description

Financial Assistance

image description

Newsroom

image description
 

UCB’s Three-Point Plan to Help Combat COVID-19 in the U.S.


With the U.S. heavily impacted by the novel coronavirus, COVID-19, UCB is committed to playing our part to contribute our scientific expertise and resources to the greater response effort happening across the country and the world. This includes expanding our assistance programs to further help patients impacted by the pandemic.

Our actions are focused on three pillars - contributing to basic research and treatment development, offering our expertise globally to increase local testing capabilities, and supporting local communities through donations and direct support to patients and partners.

Examples of our actions in the U.S. include:

  • We are actively working with the Seattle Structural Genomics Center for Infectious Disease to identify crystal structures of SARS-CoV-2 proteins.
  • In addition to providing funding support to organizations in need during this challenging time, our research facility in Bedford, Massachusetts, donated safety glasses, gloves, disposable lab coats, protective suits and gowns, and bags of strip PCR tubes from our labs to be used by healthcare institutions and researchers in Massachusetts to test and treat patients with COVID-19.  
  • UCB is also supporting healthcare professionals in our company who wish to volunteer their expertise in line with local government needs and guidance.
  • Further, we have expanded our existing Patient Assistance Program (PAP) to help eligible patients who have been impacted by COVID-19. More details are below. 
 

Frequently Asked Questions

As we navigate this unpredictable situation together as a global community, UCB’s commitment to supporting patients living with severe, chronic diseases remains unchanged. From our team at UCB, our hearts go out to all those affected by COVID-19, and we are here to help.